Is Pacira BioSciences, Stock a Good Investment?

Pacira BioSciences, Investment Advice

  PCRX
To provide specific investment advice or recommendations on Pacira BioSciences, stock, we recommend investors consider the following general factors when evaluating Pacira BioSciences,. This will help you to make an informed decision on whether to include Pacira BioSciences, in one of your diversified portfolios:
  • Examine Pacira BioSciences,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Pacira BioSciences,'s leadership team and their track record. Good management can help Pacira BioSciences, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Pacira BioSciences,'s business and its evolving consumer preferences.
  • Compare Pacira BioSciences,'s performance and market position to its competitors. Analyze how Pacira BioSciences, is positioned in terms of product offerings, innovation, and market share.
  • Check if Pacira BioSciences, pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Pacira BioSciences,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Pacira BioSciences, stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pacira BioSciences, is a good investment.
 
Sell
 
Buy
Buy
Our trade recommendations tool can cross-verify current analyst consensus on Pacira BioSciences, and to analyze the firm potential to grow in the current economic cycle. To make sure Pacira BioSciences, is not overpriced, please check all Pacira BioSciences, fundamentals, including its number of shares shorted, current ratio, working capital, as well as the relationship between the ebitda and target price . Given that Pacira BioSciences, has a price to earning of 14.34 X, we recommend you to check out Pacira BioSciences, market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your recent risk tolerance and investing horizon.

Market Performance

SolidDetails

Volatility

Very steadyDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Below AverageDetails

Economic Sensitivity

Responds to the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

HealthyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails

Examine Pacira BioSciences, Stock

Researching Pacira BioSciences,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.06. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pacira BioSciences, recorded a loss per share of 1.98. The entity had not issued any dividends in recent years.
To determine if Pacira BioSciences, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pacira BioSciences,'s research are outlined below:
Over 98.0% of the company shares are owned by institutional investors
Latest headline from simplywall.st: This Pacira BioSciences Insider Reduced Their Stake By 85

Pacira BioSciences, Quarterly Cash And Short Term Investments

453.81 Million

Pacira BioSciences, uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pacira BioSciences,. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pacira BioSciences,'s previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View
Earnings surprises can significantly impact Pacira BioSciences,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Pacira BioSciences,'s investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-07-30
2015-06-300.230.2-0.0313 
2015-04-30
2015-03-310.20.230.0315 
2019-05-02
2019-03-310.260.22-0.0415 
2014-10-30
2014-09-300.10.140.0440 
2012-11-01
2012-09-30-0.44-0.49-0.0511 
2019-08-08
2019-06-300.350.410.0617 
2017-08-02
2017-06-30-0.05-0.11-0.06120 
2016-05-02
2016-03-310.080.140.0675 

Know Pacira BioSciences,'s Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Pacira BioSciences, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pacira BioSciences, backward and forwards among themselves. Pacira BioSciences,'s institutional investor refers to the entity that pools money to purchase Pacira BioSciences,'s securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Marshall Wace Asset Management Ltd2024-06-30
971.1 K
Baillie Gifford & Co Limited.2024-06-30
806.1 K
Rock Springs Capital Management Lp2024-06-30
785 K
Nuveen Asset Management, Llc2024-06-30
711.2 K
Hhg Plc2024-06-30
698.4 K
Schroder Investment Management Group2024-06-30
616.8 K
Jpmorgan Chase & Co2024-06-30
600.6 K
Gagnon Securities Llc2024-06-30
596.6 K
Ardsley Advisory Partners2024-06-30
580 K
Blackrock Inc2024-06-30
M
Vanguard Group Inc2024-06-30
5.1 M
Note, although Pacira BioSciences,'s institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Pacira BioSciences,'s market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 796.03 M.

Market Cap

1.66 Billion

Pacira BioSciences,'s profitablity analysis

Last ReportedProjected for Next Year
Return On Tangible Assets 0.05  0.05 
Return On Capital Employed 0.06  0.06 
Return On Assets 0.03  0.03 
Return On Equity 0.05  0.05 
The company has Profit Margin (PM) of (0.13) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.
Determining Pacira BioSciences,'s profitability involves analyzing its financial statements and using various financial metrics to determine if Pacira BioSciences, is a good buy. For example, gross profit margin measures Pacira BioSciences,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pacira BioSciences,'s profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Pacira BioSciences,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pacira BioSciences,. Check Pacira BioSciences,'s Beneish M Score to see the likelihood of Pacira BioSciences,'s management manipulating its earnings.

Evaluate Pacira BioSciences,'s management efficiency

Pacira BioSciences, has return on total asset (ROA) of 0.0417 % which means that it generated a profit of $0.0417 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1148) %, meaning that it created substantial loss on money invested by shareholders. Pacira BioSciences,'s management efficiency ratios could be used to measure how well Pacira BioSciences, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.05 in 2024. Return On Capital Employed is likely to rise to 0.06 in 2024. At this time, Pacira BioSciences,'s Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.1 B in 2024, whereas Other Assets are likely to drop 0.95 in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 18.83  19.77 
Tangible Book Value Per Share 4.84  5.08 
Enterprise Value Over EBITDA 12.23  12.84 
Price Book Value Ratio 1.79  1.70 
Enterprise Value Multiple 12.23  12.84 
Price Fair Value 1.79  1.70 
Enterprise Value1.7 B1.8 B
The strategic initiatives led by Pacira BioSciences,'s management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta
0.818

Basic technical analysis of Pacira Stock

As of the 11th of November 2024, Pacira BioSciences, holds the Variance of 42.48, insignificant risk adjusted performance, and Coefficient Of Variation of (6,611). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pacira BioSciences,, as well as the relationship between them.

Pacira BioSciences,'s insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pacira BioSciences, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pacira BioSciences,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pacira BioSciences, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Shawn Cross six days ago
Acquisition by Shawn Cross of 200000 shares of Pacira BioSciences, at 16.45 subject to Rule 16b-3
 
Shawn Cross over a week ago
Acquisition by Shawn Cross of 75000 shares of Pacira BioSciences, subject to Rule 16b-3
 
Brege Laura over two weeks ago
Acquisition by Brege Laura of 1000 shares of Pacira BioSciences, at 12.81 subject to Rule 16b-3
 
Pace Gary W over three weeks ago
Disposition of 1066 shares by Pace Gary W of Pacira BioSciences, at 29.67 subject to Rule 16b-3
 
Pace Gary W over a month ago
Acquisition by Pace Gary W of 1775 shares of Pacira BioSciences, subject to Rule 16b-3
 
Daryl Gaugler over a month ago
Disposition of 500 shares by Daryl Gaugler of Pacira BioSciences, at 12.86 subject to Rule 16b-3
 
Lauren Riker over two months ago
Disposition of 5773 shares by Lauren Riker of Pacira Pharmaceuticals at 38.52 subject to Rule 16b-3
 
Brege Laura over two months ago
Acquisition by Brege Laura of 1000 shares of Pacira Pharmaceuticals at 12.81 subject to Rule 16b-3
 
Yang Michael J. over two months ago
Acquisition by Yang Michael J. of 2000 shares of Pacira Pharmaceuticals at 12.9 subject to Rule 16b-3
 
Frank Lee over two months ago
Acquisition by Frank Lee of 8264 shares of Pacira Pharmaceuticals at 12.1 subject to Rule 16b-3
 
Slonin Jonathan over three months ago
Disposition of 945 shares by Slonin Jonathan of Pacira Pharmaceuticals at 20.05 subject to Rule 16b-3
 
Slonin Jonathan over three months ago
Disposition of 914 shares by Slonin Jonathan of Pacira Pharmaceuticals at 28.46 subject to Rule 16b-3

Pacira BioSciences,'s Outstanding Corporate Bonds

Pacira BioSciences, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pacira BioSciences, uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pacira bonds can be classified according to their maturity, which is the date when Pacira BioSciences, has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understand Pacira BioSciences,'s technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Pacira BioSciences,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider Pacira BioSciences,'s intraday indicators

Pacira BioSciences, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pacira BioSciences, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Pacira BioSciences, Corporate Filings

8K
6th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
5th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F3
23rd of October 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
13th of August 2024
Other Reports
ViewVerify
Pacira BioSciences, time-series forecasting models is one of many Pacira BioSciences,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pacira BioSciences,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Pacira Stock media impact

Far too much social signal, news, headlines, and media speculation about Pacira BioSciences, that are available to investors today. That information is available publicly through Pacira media outlets and privately through word of mouth or via Pacira internal channels. However, regardless of the origin, that massive amount of Pacira data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pacira BioSciences, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pacira BioSciences, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pacira BioSciences,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pacira BioSciences, alpha.

Pacira BioSciences, Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Pacira BioSciences, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pacira BioSciences, Historical Investor Sentiment

Investor biases related to Pacira BioSciences,'s public news can be used to forecast risks associated with an investment in Pacira. The trend in average sentiment can be used to explain how an investor holding Pacira can time the market purely based on public headlines and social activities around Pacira BioSciences,. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Pacira BioSciences,'s market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pacira BioSciences, and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Pacira BioSciences, news discussions. The higher the estimate score, the more favorable the investor's outlook on Pacira BioSciences,.

Pacira BioSciences, Corporate Management

Richard KahrVice ResourcesProfile
Daryl GauglerChief OfficerProfile
Charles LaranjeiraChief Technical OfficerProfile
Christopher YoungChief OfficerProfile
Shawn CrossChief OfficerProfile
DO EllisChief OfficerProfile
III CPAChief OfficerProfile

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.